Vanguard Global Advisers
AUPH icon

Vanguard Global Advisers’s Aurinia Pharmaceuticals AUPH Stock Holding History

Vanguard Global Advisers’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$246K Buy
14,516
+7,341
+102% +$117K ﹤0.01% 2418
2026
Q1 		$106K Buy
+7,175
New +$105K ﹤0.01% 2703

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Global Advisers's AUPH Position: Q2 2026 in Review

Vanguard Global Advisers increased its Aurinia Pharmaceuticals (AUPH) stake by 102% in Q2 2026, buying an estimated $117K and bringing the position to 14,516 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #2418.

Vanguard Global Advisers first reported a position in AUPH in Q1 2026 and has held it in 2 quarters since. 278 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Vanguard Global Advisers held 14,516 shares of Aurinia Pharmaceuticals worth $246K as of Q2 2026.
  • Vanguard Global Advisers bought 7,341 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $117K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2418 holding.
  • Vanguard Global Advisers first reported a position in Aurinia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 278 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.